다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Gynecologic oncology reports, v.29, 2019년, pp.123 - 125
Ostby, Stuart A. (University of Alabama at Birmingham, Department of Obstetrics & Gynecology) , Smith, Haller J. (University of Alabama at Birmingham, Division of Gynecologic Oncology) , Leath III, Charles A. (University of Alabama at Birmingham, Division of Gynecologic Oncology)
AI-Helper
Abstract Poly-ADP ribose polymerase inhibitors (PARPi) are a promising new treatment option for patients with ovarian cancer and are moderately emetogenic. Tolerance of therapy is paramount, and uncontrolled nausea and vomiting may limit use. Although most patients will experience improvement in na...
Obstet. Gynecol. ACOG Practice Bulletin No. 189 131 e15 2018 10.1097/AOG.0000000000002456
J. Natl. Compr. Cancer Netw. Ettinger 5 12 2007 10.6004/jnccn.2007.0004 Antiemesis
Asia. Pac. J. Clin. Oncol. Friedlander 12 323 2016 10.1111/ajco.12636 Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer
Gynecol. Oncol. Gunderson 148 591 2018 10.1016/j.ygyno.2018.01.010 Management of the toxicities of common targeted therapeutics for gynecologic cancers
Clin. Cancer Res. Kristeleit 23 4095 2017 10.1158/1078-0432.CCR-16-2796 A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2 -mutated ovarian carcinoma or other solid tumors
Gynecol. Oncol. Moore 149 214 2018 10.1016/j.ygyno.2018.01.011 The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities
Am. J. Manag. Care Natale 24 S391 2018 Overview of the prevention and management of CINV
National Cancer Institute
Biomed. Res. Int. Navari 2015 1 2015 10.1155/2015/595894 Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting
N. Engl. J. Med. Navari 374 1356 2016 10.1056/NEJMra1515442 Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting
JAMA Oncol. Norquist 2 482 2016 10.1001/jamaoncol.2015.5495 Inherited mutations in women with ovarian carcinoma
Penson 2019 Olaparib Monotherapy Versus (Vs) Chemotherapy for Germline BRCA-Mutated (gBRCAm) Platinum-Sensitive Relapsed Ovarian Cancer (PSR OC) Patients (Pts): Phase III SOLO3 Trial
Lancet Oncol. Pujade-Lauraine 18 1274 2017 10.1016/S1470-2045(17)30469-2 Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Oncol. Swisher 18 75 2017 10.1016/S1470-2045(16)30559-9 Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Curr. Treat. Options in Oncol. Zimmer 19 21 2018 10.1007/s11864-018-0540-2 Update on PARP inhibitors in breast cancer
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.